TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.39
+5.55%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 4.80x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 0.38x
- Price / sales
- 3.73x
- Price / cash flow
- -0.23x
Enterprise value
- Enterprise value
- $17.3M
- EV / sales
- 2.43x
- EV / EBITDA
- -0.15x
- EV / EBIT
- -0.14x
- Market cap
- $26.5M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026